Acticor Biotech Sas Stock Fundamentals
| ALACT Stock | EUR 0.29 0.02 7.41% |
Acticor Biotech SAS fundamentals help investors to digest information that contributes to Acticor Biotech's financial success or failures. It also enables traders to predict the movement of Acticor Stock. The fundamental analysis module provides a way to measure Acticor Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acticor Biotech stock.
Acticor |
Acticor Biotech SAS Company Price To Earning Analysis
Acticor Biotech's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Acticor Biotech Price To Earning | 35.47 X |
Most of Acticor Biotech's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acticor Biotech SAS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Acticor Biotech SAS has a Price To Earning of 35.47 times. This is 58.5% lower than that of the Media sector and significantly higher than that of the Communication Services industry. The price to earning for all France stocks is 23.5% lower than that of the firm.
Acticor Biotech SAS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acticor Biotech's current stock value. Our valuation model uses many indicators to compare Acticor Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acticor Biotech competition to find correlations between indicators driving Acticor Biotech's intrinsic value. More Info.Acticor Biotech SAS is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Acticor Biotech's earnings, one of the primary drivers of an investment's value.Acticor Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acticor Biotech's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acticor Biotech could also be used in its relative valuation, which is a method of valuing Acticor Biotech by comparing valuation metrics of similar companies.Acticor Biotech is currently under evaluation in price to earning category among its peers.
Acticor Fundamentals
| Return On Equity | -3.33 | |||
| Return On Asset | -0.69 | |||
| Current Valuation | 76.26 M | |||
| Shares Outstanding | 10.52 M | |||
| Price To Earning | 35.47 X | |||
| Price To Book | 18.24 X | |||
| Price To Sales | 5.71 X | |||
| Gross Profit | 320.18 K | |||
| EBITDA | (11.92 M) | |||
| Net Income | (12.61 M) | |||
| Cash And Equivalents | 571.18 K | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 2.2 M | |||
| Debt To Equity | 662.10 % | |||
| Current Ratio | 1.19 X | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (13.75 M) | |||
| Earnings Per Share | (1.34) X | |||
| Target Price | 10.5 | |||
| Number Of Employees | 25 | |||
| Beta | 2.44 | |||
| Market Capitalization | 95.69 M | |||
| Total Asset | 17.88 M | |||
| Z Score | 25.8 | |||
| Net Asset | 17.88 M |
About Acticor Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acticor Biotech SAS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acticor Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acticor Biotech SAS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.